Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts Q3 Revenue Rise

SAN FRANCISCO, Oct. 23 – Cepheid on Tuesday posted third-quarter revenues of $2.8 million versus $2.3 for the same quarter a year ago, the company announced.

For the nine months ending September 30, 2001, revenue jumped 85 percent to $8.1 million compared to $4.4 million for the same period in 2000.

The company said the revenue increase was due to increased sales of its Smart Cycler DNA analysis systems, with sales increasing to $2 million from $1.6 million for the same quarter in 2000.

Cepheid, based in Sunnyvale, Calif., reported a net loss of $4.0 million, or 15 cents per share for the third quarter of 2001, compared to a net loss of $3.8 million, or 15 cents per share for the third quarter of 2000. 

As of September 30, 2001, the company had $29.7 million in cash and cash equivalents. 

Last week, Cepheid share price jumped due to interest in the company’s biothreat detection technology.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.